Skip Navigation


Human Molecular Genetics Advance Access originally published online on February 11, 2008
Human Molecular Genetics 2008 17(10):1446-1456; doi:10.1093/hmg/ddn033
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
17/10/1446    most recent
ddn033v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Benchoua, A.
Right arrow Articles by Brouillet, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benchoua, A.
Right arrow Articles by Brouillet, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II

Alexandra Benchoua1,{dagger}, Yaël Trioulier1,{dagger}, Elsa Diguet1, Carole Malgorn1, Marie-Claude Gaillard2, Noelle Dufour1, Jean-Marc Elalouf2, Stan Krajewski3, Philippe Hantraye1, Nicole Déglon1 and Emmanuel Brouillet1,*

1 Unité de Recherche Associée, Commissariat à l'Energie Atomique (CEA)—Centre Nationale de la Recherche Scientifique (CNRS) 2210, Service Hospitalier Frédéric Joliot, Service MIRCen, Institut d'Imagerie Biomédicale (I2BM), Direction des Sciences du Vivant, CEA, 4 place du Général Leclerc, 91401 Orsay Cedex, France 2 Commissariat à l'Energie Atomique (CEA), Institut de Biologie et Technologies de Saclay (iBiTecS), Service de Biologie Intégrative et Génétique Moléculaire (SBIGeM), Commissariat à l'Energie Atomique (CEA) Saclay, 91191 Gif- sur-Yvette Cedex, France 3 The Burnham Institute for Medical Research, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA

* To whom correspondence should be addressed at: Neuronal Death Group, URA CEA-CNRS 2210, Service Hospitalier Frédéric Joliot, Service MIRCen, I2BM, DSV, CEA, 4 place du Général Leclerc, 91401 Orsay Cedex, France. Tel: +33 169867815; Fax: +33 169867745; Email: emmanuel.brouillet{at}cea.fr

Received October 11, 2007; Accepted January 31, 2008

In neurodegenerative disorders associated with primary or secondary mitochondrial defects such as Huntington's disease (HD), cells of the striatum are particularly vulnerable to cell death, although the mechanisms by which this cell death is induced are unclear. Dopamine, found in high concentrations in the striatum, may play a role in striatal cell death. We show that in primary striatal cultures, dopamine increases the toxicity of an N-terminal fragment of mutated huntingtin (Htt-171-82Q). Mitochondrial complex II protein (mCII) levels are reduced in HD striatum, indicating that this protein may be important for dopamine-mediated striatal cell death. We found that dopamine enhances the toxicity of the selective mCII inhibitor, 3-nitropropionic acid. We also demonstrated that dopamine doses that are insufficient to produce cell loss regulate mCII expression at the mRNA, protein and catalytic activity level. We also show that dopamine-induced down-regulation of mCII levels can be blocked by several dopamine D2 receptor antagonists. Sustained overexpression of mCII subunits using lentiviral vectors abrogated the effects of dopamine, both by high dopamine concentrations alone and neuronal death induced by low dopamine concentrations together with Htt-171-82Q. This novel pathway links dopamine signaling and regulation of mCII activity and could play a key role in oxidative energy metabolism and explain the vulnerability of the striatum in neurodegenerative diseases.


{dagger} The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.